Athena Bioscience, LLC na faʻasalalau fuafuaga mo le faʻalauiloaina faapisinisi o Nexiclon XR, naʻo le tasi aso o le clonidine faʻalauteleina-faʻasalalau papala faʻaalia mo togafitiga o le toto maualuga.1 Na maua e Athena aia tatau e faʻatau ai oloa mai le Tris Pharma, Inc. ia Fepuari 2021. fa'alauiloa ua fa'atulaga mo Aperila 2022 i setete uma e 50 a Amerika.

I le averesi, e naʻo le 50% o tagata matutua e pipii atu i vailaʻau faʻamaʻi tumau2, ma i le tulaga o le maualuga o le toto maualuga (BP), o le maualalo o le tausisia e fesoʻotaʻi ma le leaga o le pulea o le BP ma iʻuga leaga, e aofia ai le stroke, myocardial infarction, fatu gau, ma maliu.3-5 Nexiclon XR o lo'o tu'uina mai ai fa'amanuiaga fa'amanino fa'ama'i e tasi o le clonidine tu'u fa'afuase'i i totonu o se papamaa faigofie e tasi i le aso.6

"Matou te talitonu o le faigofie o se laulau e tasi i le aso e mafai ona saofagā i le faʻateleina o tagata maʻi i le faʻaogaina o vailaʻau," o le tala lea a Jeff Bryant, Pule Sili o Athena. "O le tausisia lelei e tatau ona maua ai le faʻaleleia atili o togafitiga mo i latou e maua i le toto maualuga."

"O le faʻalauiloaina o Nexiclon XR o loʻo faʻaalia ai le faʻaauauina o le manuia o Tris i le aumaia o vailaʻau faʻatekonolosi eseese i maketi," o le tala lea a Tris CEO Ketan Mehta. "Ona o la latou faʻamaumauga faʻamaonia, matou te fiafia o Athena o la matou paaga, faʻalauiloa lenei oloa taua cardiovascular." O le Nexiclon e fa'avae i luga ole Tris's LiquiXR® tekonolosi tu'uina atu vaila'au, lea na mafua ai le atina'eina o le tele o oloa muamua-i-vaega.

OA MEA E AVEA MAI LENEI TUSI:

On average, only 50% of adults adhere to chronic disease medications2, and in the case of high blood pressure (BP), lower levels of adherence are associated with worse BP control and adverse outcomes, including stroke, myocardial infarction, heart failure, and death.
“We believe the convenience of a once-daily tablet can contribute to increased patient adherence to medication regimens,”.
The launch is set for April 2022 in all 50 U.